Kyverna Therapeutics (KYTX) announced the appointments of Sravan Emany and Andrew Miller, Ph.D. to its Board of Directors. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped down from the Board. Emany currently serves as the CFO of Beam Therapeutics (BEAM). Most recently, Dr. Miller was the Founder and President of R&D at Karuna Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing
- Kyverna Therapeutics appoints Pujols as Chief Technology Officer
- Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating
- Kyverna Therapeutics Names Christi Shaw Executive Board Chair
- Kyverna Therapeutics provides corporate update, priorities for 2026